DISCLAIMER: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 17, 2026

To whom it may concern,

Company name:	Heartseed Inc.
Representative:	Keiichi Fukuda, MD/PhD/FACC, CEO, Representative Director of the Board
Securities code:	219A, Tokyo Stock Exchange
Inquiries:	Akira Masuda, Head of Strategic Finance and IR Department TEL: +81-(0)3-6665-8068 (IR)

Notice Regarding Application for Marketing Authorization Holder License for Regenerative Medical Products

Heartseed Inc. (the "Company") hereby announces that it has today filed an application for a "Marketing Authorization Holder License for Regenerative Medical Products" with the Tokyo Metropolitan Government, as detailed below.

1. Reasons and Background for the Application

The Company is currently advancing the development of allogeneic iPS cell-derived cardiomyocyte spheroids for the treatment of severe heart failure. With a view toward future applications for marketing authorization approval, as well as domestic commercialization and market launch, the Company has filed an application for a Marketing Authorization Holder License for Regenerative Medical Products with the Tokyo Metropolitan Government. Marketing authorization holders of regenerative medical products are required by law to establish and maintain systems that comply with "GQP (Good Quality Practice)" and "GVP (Good Vigilance Practice)" standards regarding product quality management and post-marketing safety management under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the "PMD Act").

2. Positioning in the Company's Business Development

The Company is steadily progressing with its development, including clinical trials in Japan. This application for a marketing authorization holder license marks a transition from the research and development phase to a practical operation phase for future commercialization and market launch. The Company will continue to work on further strengthening its legal compliance systems in line with GQP and GVP standards.

There is no revision to the latest earnings forecast for the fiscal year ending December 31, 2026.

(Cautionary notice on forward-looking information)

The financial results forecasts and other forward-looking information contained in this document are based on the information currently available to the Company and certain assumptions considered reasonable by the Company. It is not a guarantee that the forecasts will be achieved, and actual results may differ significantly from such forecasts depending on various factor